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without false positive results. The CAZ-based assay was more reliable in detecting
AmpC alone, while the CTX-based assay performed better in identifying co-producers
of ESBL and AmpC. There was no difference in detection of ESBL and MBL producers.
The findings of the present study suggest that use of the RMP assay with particular β-
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existence of β-lactamases within 6 h. This assay is applicable to carry out in any
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Abstract 25 
Dissemination of antibiotic resistance in Enterobacteriaceae mediated by AmpC, ESBL and 26 
MBL β-lactamases is clinically significant. A simple, rapid method for the detection of these 27 
resistance phenotypes would greatly improve chemotherapeutic recommendation. This 28 
technology would provide valuable input in our surveillance of resistance on a global stage, 29 
particularly if the methodology could be applicable to resource poor settings. A resazurin 30 
microtitre plate (RMP) assay incorporating cloxacillin (CX), clavulanic acid (CA), and 31 
EDTA for the rapid phenotypic identification of AmpC, ESBL, MBL and the co-existence of 32 
β-lactamases has been developed. A total of 44 molecularly characterised Enterobacteriaceae 33 
clinical isolates producing AmpCs, ESBLs,  co-producers of ESBL and AmpC, MBLs, and 34 
co-producers of ESBL and MBL  were phenotypically examined using the RMP assay. The 35 
ceftazidime (CAZ)-based and cefotaxime (CTX)-based RMP assay successfully detected all 36 
15 AmpC, 12  ESBL, 9 MBL producers,  6 ESBL-AmpC co-producers, and 2 ESBL-MBL 37 
co-producers without false positive results. The CAZ-based assay was more reliable in 38 
detecting AmpC alone, while the CTX-based assay performed better in identifying co-39 
producers of ESBL and AmpC. There was no difference in detection of ESBL and MBL 40 
producers. The findings of the present study suggest that use of the RMP assay with 41 
particular β-lactamase inhibitors explicitly detects three different β-lactamases, as well as co-42 
existence of β-lactamases within 6 h. This assay is applicable to carry out in any laboratory, is 43 
cost-effective and easy to interpret. It could be implemented in screening patients, controlling 44 
infection and for surveillance purposes. 45 
 46 
 47 
 48 
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Introduction 49 
Infections caused by multidrug-resistant Enterobacteriaceae are among one of the most 50 
serious threats to human health (Tangden & Giske,2015). The production of β-lactamases 51 
mediated by both chromosomal and plasmid genes are crucial mechanisms of antibiotic 52 
resistance. AmpC β-lactamases were the first bacterial enzymes found to inactivate penicillin, 53 
first identified in Escherichia coli in 1940 prior to penicillins being medically introduced 54 
(Jacoby,2009). Plasmid-mediated AmpC β-lactamase (pAmpC)-producing 55 
Enterobacteriaceae can confer resistance to multiple antibiotics, such as penicillins, 56 
oxyimino-cephalosporins (e.g. cefotaxime, ceftazidime and ceftriaxone) and 7-α-57 
methoxycephalosporins (e.g. cefoxitin and cefotetan) (Gupta et al.,2012). CMY-type β-58 
lactamases, especially CMY-2 are the highest prevalence of pAmpC in E. coli that have been 59 
commonly identified in many regions of the world (Doi et al.,2010; Liebana et al.,2013). 60 
These enzymes are inhibited by boronic acid (BA), and its derivatives (Beesley et al.,1983) 61 
and cloxacillin (CX) (Jacoby,2009). AmpC β-lactamases are poorly inhibited by clavulanic 62 
acid (CA) (Bush et al.,1995). 63 
Enterobacteriaceae can also produce powerful enzymes called extended-spectrum β-64 
lactamases (ESBLs), which characteristically confer  resistance to penicillins, cephalosporins, 65 
and monobactams, but remain susceptible to β-lactamase inhibitors  (CA, tazobactam, 66 
sulbactam) cephamycins and carbapenems (Bradford,2001). The majority of ESBL-67 
producing clinical isolates of Enterobacteriaceae harbour TEM-, SHV-, and CTX-M-type β-68 
lactamases. These enzymes have gained medical significance in both hospital and community 69 
settings, across all ages and demographics (Lukac et al.,2015). Furthermore, carbapenem-70 
inactivating β-lactamase, namely metallo-β-lactamase (MBL) has been identified with 71 
increasing prevalence over the past few years (Patrice et al.,2011). MBL can hydrolyse all 72 
classes of bicyclic β-lactams (penicillins, cephalosporins and carbapenems) and all 73 
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commercially available β-lactamase inhibitors (such as CA), but lack hydrolytic activity 74 
toward monocyclic β-lactams (monobactams) (Bebrone,2007). The activity of this enzyme is 75 
facilitated by zinc-ions to degrade β-lactams and is inhibited by metal-chelating 76 
ethylenediaminetetraacetic acid (EDTA) and dipicolinic acid (Walsh et al.,2005). 77 
Imipenemase (IMP), Verona integron-encoded metallo-β-lactamase (VIM), and New Delhi 78 
metallo-β-lactamase (NDM) are common widespread MBLs. These metalloenzymes were 79 
frequently identified in Pseudomonas aeruginosa and Acinetobacter spp., but currently an 80 
increasing emergence of these have been documented in Enterobacteriaceae worldwide (Patel 81 
& Bonomo,2013).  82 
The early detection of the presence of these resistant strains at the phenotypic level would aid 83 
infection-control practitioners to minimise the dissemination of these bacteria and also help to 84 
select appropriate antimicrobial treatment (Pitout & Laupland,2008).  The development of a 85 
rapid method for the identification of these β-lactamase producing strains in clinical practice 86 
is a challenging issue. The resazurin (Alamar blue) reduction assay is a simple and 87 
inexpensive colorimetric method that has extensively been used as an indicator for cell 88 
growth, cell viability, toxicity and indirect antimicrobial susceptibility testing.  This dye is 89 
non-toxic to cells and stable in culture media. A blue coloured resazurin is irreversibly 90 
converted to a pink coloured resorufin by active cells (O'Brien et al.,2000; Palomino et 91 
al.,2002). The present study uses the resazurin dye in conjunction with three distinct β-92 
lactamase inhibitors, CX, CA, and EDTA, for the phenotypic detection of AmpC, ESBL, 93 
MBL and co-expression of β-lactamases.   94 
Methods 95 
Bacterial Isolates, Chemicals and Antibiotics 96 
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A total of 44 Enterobacteriaceae clinical isolates were used in this study. The bacterial strains 97 
included E. coli (n=13), Klebsiella pneumoniae (n=16) , Enterobacter aerogenes (n=2), 98 
Enterobacter cloacae (n=8), Morganella morganii (n=1), Citrobacter freundii (n=3), and 99 
Klebsiella ozaenae (n=1); 15 were AmpC producers, 12 were ESBL producers, 6 were ESBL 100 
and AmpC co-producers,  9 were MBL producers, and 2 were ESBL and MBL co-producers 101 
(Table 1).  The control strains were E. coli ATCC 25922 (non-β-lactamase producer), E. 102 
cloacae ATCC BAA-1143 (blaACT-32), E. coli NCTC 13352 (blaTEM-10) and E. coli NCTC 103 
13353 (blaCTX-M-15).  All organisms had been identified by biochemical, phenotypic and 104 
molecular tests including combined disc, PCR and sequencing methods as previously 105 
described (Pérez-Pérez & Hanson,2002; Woodford,2010; Roschanski et al.,2014). All 106 
antibiotics and chemicals employed were purchased from Sigma Aldrich, UK. Mueller-107 
Hinton Broth (MHB) powder was obtained from Scientific Laboratory Supplies, UK.  108 
Antibiotics and β-lactamase inhibitors were prepared in accordance with the recommendation 109 
of manufacturers.  110 
Resazurin Microtitre Plate Assay (RMP) 111 
The production of ESBL, AmpC, MBL and co-β-lactamases was phenotypically detected 112 
using the RMP assay based upon the broth microdilution method. An overnight culture of the 113 
appropriate test bacterium was pelleted for 10 min and washed twice with normal saline at 114 
4,000 rpm for 5 min before adjustment to a 0.5 McFarland suspension according to the 115 
recommendations of the Clinical Laboratory Standards Institute (CLSI) in document M07-A9 116 
(Clinical Laboratory Standards Institute,2012). An aliquot (20 µL) of a 5 x 106 CFU/mL of 117 
organism were added to the wells containing 180 µL of MHB, amended with resazurin at a 118 
concentration of 20 µg/mL, and serial twofold dilution of cefotaxime (CTX) or ceftazidime 119 
(CAZ) with a fixed concentration of β-lactamase inhibitors; CX at 200 µg/mL, EDTA at 0.5 120 
mM, and CA at 4 µg/mL.  Following incubation at 37 ºC, the lowest concentration showing 121 
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no colorimetric change from blue to pink within 6 h was considered as the MIC value.  122 
Interpretation criteria of the result obtained is explained in Table 2.  The experiment was 123 
carried out in three independent replicates. 124 
 125 
Results and Discussion 126 
β-Lactam antibiotics are most frequently prescribed for the treatment of infections caused by 127 
Gram negative bacteria, in particular Enterobacteriaceae. Resistance to β-lactams is mediated 128 
by both plasmid- and chromosomally-encoded β-lactamases. The rapid global spread of these 129 
resistant bacteria is facilitated by inter- and intra-species gene transmission, poor sanitation 130 
and hygiene, increasing global trade, international travel and tourism, and antibiotic misuse 131 
(Rogers et al.,2011; Aung et al.,2012; Laxminarayan et al.,2013). The consequence is 132 
increased treatment failure and health risks. The development of rapid and accurate methods 133 
for the detection and characterisation of different types of β-lactamase remains an urgent 134 
necessity. The early detection is crucial in guiding appropriate antimicrobial therapy. The 135 
common conventional detection methods for the production of β-lactamase are still time-136 
consuming (approximately 24 to 48 h) (Nordmann et al.,2012). Here, we developed the RMP 137 
assay with inhibitor-based methods for the early phenotypic detection of ESBL, AmpC, 138 
MBL, and co-production of β-lactamases. 139 
The findings from the RMP assay were very simple and clear to interpret as illustrated in 140 
Figure 1.  The results showed that the RMP CAZ-based assay was more reliable than the 141 
CTX-based assay for early AmpC detection. An eightfold or higher MIC ratio was observed 142 
when comparing the well without CX to other wells only for AmpC producers. Other MIC 143 
ratios revealed values lower than 8, which indicated negative results for ESBL and MBL 144 
producers. The CAZ-based assay successfully detected 15 of all 15 AmpC-producing 145 
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isolates, while 14 of 15 strains were detected by the CTX-based RMP assay. The AmpC 146 
control strain clearly showed hyperproduction of AmpC β-lactamase indicated by a high MIC 147 
value in the well without an AmpC inhibitor (Table 1). The production of AmpC β-lactamase 148 
in Gram negative pathogens, especially Enterobacteriaceae is clinically important. Accurate 149 
and rapid detection methods for these enzymes should be urgently developed. This would 150 
ensure effective antimicrobial therapy and improve clinical management as a consequence of 151 
clinical failure in the treatment of AmpC producers with broad-spectrum cephalosporins 152 
(Polsfuss et al.,2011). Cloxacillin is well-described as an AmpC β-lactamase inhibitor, but it 153 
cannot distinguish between plasmid-mediated and chromosome-borne AmpC (Jacoby,2009). 154 
This study found that CAZ in conjunction with CX and EDTA was more sensitive for early 155 
detection of AmpC-producing Enterobacteriaceae compared with the CTX-based assay. This 156 
result is consistent with a previous report where CAZ showed the best performance compared 157 
with CTX, cefmetazole, or moxalactam in combination with 3-aminophenylboronic acid 158 
(APB) in detection of AmpC β-lactamases (Yagi et al.,2005).  Another previous research 159 
study reported no difference in sensitivity and specificity between CTX- and CAZ-based 160 
detection in the presence of CA with and without BA in detection of pAmpC (Jeong et 161 
al.,2009).  In this study, some AmpC producers such as, K. pneumoniae 2001 (DHA-1), E. 162 
coli 2002 (DHA-1), and M. morganii 2010 were partially inhibited by CX as indicated by the 163 
high MIC values after exposure to CX. In those isolates we suggest that the resistance was 164 
not only mediated by AmpC β-lactamase, but might also be conferred by alteration in the 165 
permeability of the outer membrane. 166 
The MIC ratio for wells without CA compared to wells with CA gave a value ≥8 in all tested 167 
ESBL-producing Enterobacteriaceae employed in this study. The findings unambiguously 168 
indicated that both CAZ-based and CTX-based assays gave reproducible results in detecting 169 
all ESBL isolates. Even though CLSI has recommended a standardised confirmatory test for 170 
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ESBL-producing Enterobacteriaceae, previous reports found that using CTX and CAZ alone 171 
and in combination with CA demonstrated a high percentage of false-negative results in 172 
detection of ESBL producers due to co-production of β-lactamase enzymes (Jeong et 173 
al.,2009). In the current study inhibitor-based methods using three different β-lactamase 174 
inhibitors were applied to improve the sensitivity and specificity for phenotypic detection of 175 
ESBL in clinical isolates of Enterobacteriaceae. This modification allows the successful 176 
identification of all ESBLs in both CAZ-and CTX-based assays.  Several techniques for 177 
detecting the production of ESBL have been proposed such as, double-disc synergy test, Etest 178 
and automated methods. The sensitivities and specificities for the double-disc test and Etest 179 
were 80% to 95%, whilst automated susceptibility methods were 80% to 99% (Drieux et 180 
al.,2008; Gazin et al.,2012). In addition, the ESBL NDP (Nordmann/Dortet/Poirel) test has 181 
been developed for rapid detection with an excellent sensitivity and specificity of 92.6% and 182 
100%, respectively. However, this test was limited to detecting ESBL without presence of 183 
AmpC or other β-lactamases (Nordmann et al.,2012).  184 
All MBL producers were detected by the RMP assay, including 9 MBL-producing isolates 185 
and 2 co-producers of ESBL and MBL. The CTX-based assay gave similar results with the 186 
CAZ-based assay for the rapid phenotypic detection of MBL producers.  The MIC ratio of 187 
non-β-lactamase-producing E. coli ATCC 25922 for both CTX- and CAZ-based assays was 188 
1, suggesting no ESBL, AmpC, and MBL production in this bacterium.  A raised global 189 
dissemination of MBL-producing Enterobacteriaceae has drawn researchers to develop 190 
reliable techniques for detection of MBLs (Hattori et al.,2013). Yan and colleagues 191 
conducted double-disc, combined disc, and Etest techniques for the detection of Gram 192 
negative bacilli producing MBLs. They found that the 2-mercaptopropionic acid (2-MPA) 193 
double-disc test using CAZ and cefepime, with and without CA, exhibited highest sensitivity 194 
(100%) compared with the combined disc test (86.7%) and Etest (36.7%). Even the double-195 
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disc test showed high sensitivity, but there were some disadvantages, including subjective 196 
interpretation of results in some samples, and also volatile and odorous properties of 2-MPA 197 
(Yan et al.,2004).  More recently, double-disc synergy tests using sodium mercaptoacetic 198 
acid (SMA) and EDTA as MBL inhibitors, and CAZ, imipenem and meropenem as indicator 199 
antibiotics have emerged. The results showed that CAZ in combination with SMA can detect 200 
only MBL-producing strains, whereas a combination of meropenem and SMA revealed the 201 
best performance (sensitivity, 79.1%; specificity, 100%) in detection of co-production of β-202 
lactamases (Hattori et al.,2013). Yagi and colleagues also suggested the broth microdilution 203 
method incorporating CAZ or CTX with SMA for successful detection of IMP-type MBL 204 
(Yagi et al.,2005). Our findings revealed a good performance in the RMP assay for either 205 
MBL alone or in combination with ESBL.   206 
ESBL and AmpC co-producers were positively detected as indicated by a ≥8 MIC ratio for 207 
wells containing either CA or CX compared to wells containing both CA and CX.  The CTX-208 
based RMP assay was more reliable in phenotypic characterisation of the co-existence of 209 
ESBL and AmpC β-lactamase compared with the CAZ-based RMP assay (Table 1). Co-210 
production of different types of β-lactamase in the same strain are one of the most common 211 
causes of phenotypic detection failure. The most prevalent isolates co-producing pAmpCs 212 
and ESBLs are K. pneumoniae and E. coli (Goossens & Grabein,2005). These co-β-213 
lactamases may result in false-negative tests for the detection of ESBLs or AmpCs 214 
(Coudron,2005). A method that can distinguish between ESBLs and pAmpCs is important for 215 
both treatment and epidemiology (Song et al.,2007). Furthermore, co-expression of MBL 216 
together with ESBLs (commonly CTX-M-type) and AmpC β-lactamases (mostly CMY-217 
enzymes) appears to be difficult to detect. Consequently, these may be a major cause of false-218 
negative tests for detection of co-MBL, AmpC and ESBL in Gram negative pathogens 219 
(Hattori et al.,2013; Tangden & Giske,2015).   220 
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Although simple phenotypic tests for ESBL, AmpC and MBL have been proposed  by several 221 
researchers, and indeed conducted in clinical laboratory practice (Yagi et al.,2005; Jeong et 222 
al.,2009), there is no standard guideline for phenotypic detection of AmpC that has been 223 
recommended by the CLSI (Clinical Laboratory Standards Institute,2012). Broth 224 
microdilution methods have become more popular in clinical diagnostic laboratories since 225 
semi-automated antimicrobial susceptibility test systems have become commercially 226 
available. This test generally involves overnight incubation in the determination of antibiotic 227 
susceptibility profiling (Yagi et al.,2005). The present study using the RMP assay allows for 228 
the detection of ESBLs, AmpCs, MBLs and co-producers within 6 h. RMP assays could 229 
allow clinicians to detect these enzymes in rural clinical laboratories in resource poor 230 
settings. 231 
Phenotypic tests for β-lactamase production are carried out in most clinical diagnostic 232 
laboratories because they are easy to implement and are cost effective. This detection is 233 
important in terms of epidemiological purposes and to restrict the dissemination of β-234 
lactamase-mediated resistance mechanisms (Poulou et al.,2014). Phenotypic tests alone 235 
cannot distinguish between the specific bla genes of β-lactamases (TEM, SHV, CTX for 236 
ESBLs, CMY, MOX for AmpCs, and IMP, NDM, VIM for MBLs) (Pitout & Laupland,2008; 237 
Pitout et al.,2010), therefore, several reference laboratories use molecular methods for 238 
identification of those β-lactamase-encoded genes. Molecular approaches are restricted 239 
largely to reference laboratories for epidemiological studies because of the complexity and 240 
diversity of distinct point mutations of β-lactamases (Sundsfjord et al.,2004).  241 
Although we used small samples of clinical isolates, a previous study found that use of CTX 242 
or CAZ combined with CA for detecting ESBL and CTX or CAZ plus BA for identifying 243 
pAmpC demonstrated 100% in both sensitivity and specificity (Jeong et al.,2009).  In our 244 
study, the RMP assay detected all ESBL, AmpC, and ESBL-AmpC co-producers. Therefore, 245 
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we expect that our RMP assay could reach 100% in sensitivity and specificity similar to 246 
previous reports when a larger number of clinical isolates are tested. This assay can 247 
successfully distinguish co-expression of ESBL and AmpC or ESBL and MBL in the same 248 
strain. In future work, isolates with other resistance mechanisms, including alteration of 249 
permeability of bacterial membrane and modification of membrane proteins should be 250 
included in total isolates screened with RMP assay. The early detection of β-lactamase 251 
enzymes may reduce a delay in the initiation of appropriate antimicrobial therapy and could 252 
produce effective treatment. RMP assay is a useful method that can detect and characterise 253 
ESBL, AmpC, MBL and co-production of ESBL and AmpC or ESBL and MBL within 6 h. It 254 
could be implemented in microbiological diagnostic laboratories in resource poor areas to 255 
help clinicians screen patients, control infection, and provide epidemiological surveillance.   256 
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Table 1.  Bacterial strains used in this investigation and results of phenotypic β-lactamase detection at 
6 h using CTX -basedABCD and CAZ-basedabcd assays. 
 
CTX= cefotaxime; CAZ= ceftazidime; CA= clavulanic acid (4 µg/ml); CX=cloxacillin (200 µg/ml); EDTA = 
ethylenediaminetetraacetic acid (0.5mM);A (a) = CTX (CAZ)+ CX+EDTA; B (b) = CTX(CAZ)+CA+EDTA;C 
(c) = CTX(CAZ)+CA+CX; D (d) = CTX (CAZ)+CA+CX+EDTA. * control strain
Strains 
Resistance  
Mechanism 
MICs of CTX -based  
(µg/ml) 
 
MICs of  CAZ -based   
(µg/ml) 
 Phenotypic 
results 
A B C D a b   c d 
 *E. coli ATCC 25922 Negative control ≤0.06 ≤0.06 ≤0.06 ≤0.06 
 
≤0.06 ≤0.06 ≤0.06  ≤0.06 None 
 K. pneumoniae  2001 DHA-1 4 ≥256 8 4 
 
8 ≥256 16 8 AmpC 
 E. coli 2002 DHA-1 4 32 4 4 
 
16 ≥256 16 16 AmpC 
 E. coli  2003 AmpC ≤0.06 0.25 ≤0.06 ≤0.06 
 
0.125 1 0.125 0.125 AmpC 
 E. coli 2004 CMY-2 ≤0.06 32 ≤0.06 ≤0.06 
 
≤0.06 64 ≤0.06 ≤0.06 AmpC 
 E. coli 2005 AmpC ≤0.06 2 ≤0.06 ≤0.06 
 
0.125 4 0.125 0.125 AmpC 
 E.coli 2006 CMY-2 0.25 8 0.125 0.125 
 
0.25 4 0.25 0.25 AmpC 
 E. aerogenes  2007 ACT-31 ≤0.06 32 ≤0.06 ≤0.06 
 
≤0.06 4 ≤0.06 ≤0.06 AmpC 
 E. cloacae  2008 FOX ≤0.06 16 ≤0.06 ≤0.06 
 
0.125 32 0.125 0.125 AmpC 
 E. cloacae  2009 ACR-32 0.125 64 0.125 0.125 
 
0.125 32 0.125 0.125 AmpC 
 M. morganii 2010 AmpC 2 64 2 2 
 
8 ≥256 8 8 AmpC 
 E. cloacae  2011 AmpC ≤0.06 64 ≤0.06 ≤0.06 
 
≤0.06 32 ≤0.06 ≤0.06 AmpC 
 C. freundii 2026 CMY-112 ≤0.06 32 ≤0.06 ≤0.06 ≤0.06 32 ≤0.06 ≤0.06 AmpC 
 K. pneumoniae 2020 FOX ≤0.06 2 ≤0.06 ≤0.06  0.5 16 0.5 0.5 AmpC 
 E. coli  2021 FOX-3 ≤0.06 0.5 ≤0.06 ≤0.06  ≤0.06 8 0.125 0.125 AmpC 
 E. cloacae 2022 ACT-32 4 128 4 4  2 ≥256 2 2 AmpC 
 *E. cloacae BAA-1143 ACT-32 4 128 4 4  2 128 4 4 AmpC 
 E. coli  1004 TEM-214 64 0.125 0.125 0.125  16 0.25 0.25 0.125 ESBL 
 E. coli  1005 CTX-M-3 1 ≤0.06 ≤0.06 ≤0.06  0.5 ≤0.06 ≤0.06 ≤0.06 ESBL 
 E. coli 1006 CTX-M-3 64 0.125 ≤0.06 ≤0.06  1 0.125 0.125 0.125 ESBL 
 E. coli  1008 CTX-M-3 ≥256 0.25 0.125 0.125  64 1 0.5 0.5 ESBL 
 E. coli  1009 TEM 32 0.125 ≤0.06 ≤0.06  4 0.125 0.125 0.125 ESBL 
 K. pneumoniae 1010 CTX-M-15,SHV-27 64 ≤0.06 ≤0.06 ≤0.06  16 ≤0.06 ≤0.06 ≤0.06 ESBL 
 K. pneumoniae 1012 SHV-27,TEM-53 64 ≤0.06 ≤0.06 ≤0.06  32 0.125 0.125 0.125 ESBL 
 K. pneumoniae 1013 SHV-27 32 ≤0.06 ≤0.06 ≤0.06  32 0.5 0.5 0.5 ESBL 
 K. pneumoniae 1015 SHV-27,TEM-71 16 ≤0.06 ≤0.06 ≤0.06  8 0.125 0.125 0.125 ESBL 
 *E. coli  13352 TEM-10 1 ≤0.06 ≤0.06 ≤0.06  128 0.5 0.5 0.5 ESBL 
 *E. coli  13353 CTX-M-15 128 ≤0.06 ≤0.06 ≤0.06  32 ≤0.06 ≤0.06 ≤0.06 ESBL 
 K. pneumoniae 1021 SHV-18 128 ≤0.06 ≤0.06 ≤0.06  32 ≤0.06 ≤0.06 ≤0.06 ESBL 
 K. pneumoniae 1022 SHV-27,TEM-115 32 ≤0.06 ≤0.06 ≤0.06  16 ≤0.06 ≤0.06 ≤0.06 ESBL 
 K. pneumoniae 1023 SHV-27,CTX-M-15 64 ≤0.06 ≤0.06 ≤0.06  16 ≤0.06 ≤0.06 ≤0.06 ESBL 
 E. cloacae  3007 CTX-M-9, MIR-1 ACT-1 16 64 ≤0.06 ≤0.06  1 32 ≤0.06 ≤0.06 AmpC+ESBL 
 E. cloacae 3009 TEM-214,SHV-12+ ACT 16 1 0.125 ≤0.06  4 0.25 ≤0.06 ≤0.06 AmpC+ESBL 
 E. aerogenes  3022 SHV-12,CTX-M-9+ ACT-32 2 32 ≤0.06 ≤0.06  0.5 2 0.25 0.25 AmpC+ESBL 
 E. coli  3003 CTX-M-9+AmpC 4 32 0.125 ≤0.06  32 16 0.125 ≤0.06 AmpC+ESBL 
 C. freundii  3004 CTX-M-3+AmpC 2 32 ≤0.06 ≤0.06  0.25 4 ≤0.06 ≤0.06 AmpC+ESBL 
 C. freundii 3005 CTX-M-3+ ACT-1 4 32 ≤0.06 ≤0.06  32 4 0.25 0.25 AmpC+ESBL 
 K. ozaenae  4031 IMP-1 ≤0.06 0.125 32 ≤0.06  0.5 0.5 128 ≤0.06 MBL 
 K. pneumoniae  4033 VIM-1+SHV-102 4 ≤0.06 32 ≤0.06  128 ≤0.06 ≥256 ≤0.06 MBL+ESBL 
 K. pneumoniae  4034 VIM-1+SHV-12 8 ≤0.06 8 ≤0.06  128 ≤0.06 128 ≤0.06 MBL+ESBL 
 K. pneumoniae  4036 NDM-1 ≤0.06 ≤0.06 ≥256 ≤0.06  ≤0.06 ≤0.06 ≥256 ≤0.06 MBL 
 K. pneumoniae  4025 VIM-type 0.125 0.125 ≥256 0.125  ≤0.06 ≤0.06 ≥256 ≤0.06 MBL 
 E. cloacae  4004 NDM-1 ≤0.06 ≤0.06 ≥256 ≤0.06  ≤0.06 ≤0.06 ≥256 ≤0.06 MBL 
 K. pneumoniae  4017 VIM-type ≤0.06 ≤0.06 ≥256 ≤0.06  ≤0.06 ≤0.06 ≥256 ≤0.06 MBL 
 K. pneumoniae  4023 NDM-1 0.125 0.125 1 0.125  ≤0.06 ≤0.06 2 ≤0.06 MBL 
 K. pneumoniae  4024 NDM-1 ≤0.06 ≤0.06 ≥256 ≤0.06  ≤0.06 ≤0.06 ≥256 ≤0.06 MBL 
 E. coli  4011 NDM-1 ≤0.06 ≤0.06 ≥256 ≤0.06  ≤0.06 ≤0.06 ≥256 ≤0.06 MBL 
 E. cloacae  4005 NDM 8 8 ≥256 4  2 2 ≥256 1 MBL 
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Table 2 Interpretation criteria of ceftazidime (CAZ)-based and cefotaxime (CTX)-based 
detection using resazurin microtitre plate assay. 
 
MIC ratio ≥8  ESBL AmpC MBL 
A/D  or  a/d + - - 
B/D  or b/d - + - 
C/D or c/d - - + 
A/D  or  a/d  and  B/D  or b/d + + - 
A/D  or  a/d  and   C/D or c/d + - + 
B/D  or b/d  and   C/D or c/d - + + 
A/D  or  a/d  and  B/D  or b/d and  C/D or c/d + + + 
 
A (a) = CTX (CAZ)+ CX+EDTA 
B (b) = CTX(CAZ)+CA+EDTA 
C (c) = CTX(CAZ)+CA+CX 
D (d) = CTX (CAZ)+CA+CX+EDTA 
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